The effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO): a systematic review protocol

详细信息    查看全文

• 作者：Mohammad O. Tallouzi ; David J. Moore ; Melanie Calvert…
• 关键词：Systematic review ; Macular oedema ; Macular edema ; Uveitis ; Management ; Pharmacological agents ; Meta ; analysis
• 刊名：Systematic Reviews
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：5
• 期：1
• 全文大小：441 KB
• 参考文献：1.Durrani O, Meads C, Murray P. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218(4):223–36.CrossRef PubMed
  2.Williams GJ, Brannan S, Forrester JV, Gavin MP, Paterson-Brown SP, Purdie A, et al. The prevalence of sight-threatening uveitis in Scotland. Br J Ophthalmol. 2007;91(1):33–6.PubMedCentral CrossRef PubMed
  3.Abdulaal MR, Abiad BH, Hamam RN. Uveitis in the aging eye: incidence, patterns, and differential diagnosis. J Ophthalmol. 2015;2015:1–8.CrossRef
  4.Rao NA. Uveitis in developing countries. Indian J Ophthalmol. 2013;61(6):253–4.PubMedCentral CrossRef PubMed
  5.Vadot E, Barth E, Billet P. Epidemiology of uveitis—preliminary results of a prospective study in Savoy. Uveitis update Amsterdam: Elsevier. 1984;136:36–40.
  6.Rothova A, Suttorp-van Schulten M, Treffers WF, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–6.PubMedCentral CrossRef PubMed
  7.Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103(2):234–5.CrossRef PubMed
  8.Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–16.CrossRef PubMed
  9.Lardenoye CW, Van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113(8):1446–9.CrossRef PubMed
  10.Davis J. Current concepts in the management of uveitic macular edema. Advanced Studies in Ophthalmology. 2010;7(2):60–6.
  11.Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of Snellen versus ETDRS charts in clinical practice (an AOS thesis). Trans Am Ophthalmol Soc. 2009;107:311–24.PubMedCentral PubMed
  12.Levin MH, Pistilli M, Daniel E, Gangaputra SS, Nussenblatt RB, Rosenbaum JT, et al. Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology. 2014;12(2):588–95. e1.CrossRef
  13.Taylor SR, Lightman SL, Sugar EA, Jaffe GJ, Freeman WR, Altaweel MM, et al. The impact of macular edema on visual function in intermediate, posterior, and panuveitis. Ocul Immunol Inflamm. 2012;20(3):171–81.PubMedCentral CrossRef PubMed
  14.Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol. 2004;122(3):330–5.CrossRef PubMed
  15.Reinthal E, Völker M, Freudenthaler N, Grüb M, Zierhut M, Schlote T. Optical coherence tomography in the diagnosis and follow-up of patients with uveitic macular edema. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2004;101(12):1181–8.CrossRef
  16.Karim R, Sykakis E, Lightman S, Fraser-Bell S. Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis. Clin Ophthalmol. 2013;7:1109–44.PubMedCentral CrossRef PubMed
  17.Kempen JH, Sugar EA, Jaffe GJ, Acharya NR, Dunn JP, Elner SG, et al. Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema. Ophthalmology. 2013;120(9):1852–9.PubMedCentral CrossRef PubMed
  18.Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11):1916.e1–7.CrossRef
  19.Venkatesh P, Kumar CS, Abbas Z, Garg S. Comparison of the efficacy and safety of different methods of posterior subtenon injection. Ocul Immunol Inflamm. 2008;16(5):217–23.CrossRef PubMed
  20.Menezo V, Lau C, Comer M, Lightman S. Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis. Clin Exp Ophthalmol. 2005;33(1):16–21.CrossRef
  21.McCluskey PJ, Towler HM, Lightman S. Regular review: management of chronic uveitis. BMJ. 2000;320(7234):555–8.PubMedCentral CrossRef PubMed
  22.Deuter CM, Kotter I, Gunaydin I, Stubiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93(7):906–13.CrossRef PubMed
  23.Neri P, Mariotti C, Cimino L, Mercanti L, Giovannini A. Long-term control of cystoid macular oedema in noninfectious uveitis with Mycophenolate Mofetil. Int Ophthalmol. 2009;29(3):127–33.CrossRef PubMed
  24.Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology. 2009;116(4):797–801.CrossRef PubMed
  25.Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138(4):648–50.CrossRef PubMed
  26.Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol. 2009;148(2):303-9. e2.CrossRef
  27.NIHR, Research NIfH. James Lind Alliance | Ocular inflammatory disease top 10 2015 [15/10/2015].Available from: http://​www.​jla.​nihr.​ac.​uk/​top-tens/​sight-loss-and-vision-psp-top-10s/​ocular-inflammatory-disease-top-10 .
  28.Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.CrossRef PubMed
  29.Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: Cochrane book series. Chichester, England, Hoboken, NJ: Wiley Blackwell; 2008.CrossRef
  30.Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2000 [20/10/2015].Available from: http://​www.​ohri.​ca/​programs/​clinical_​epdemiology/​Oxford.​asp .
  31.Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRef PubMed
  32.Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61(10):991–6.CrossRef PubMed
  33.Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417–28.CrossRef PubMed
  34.Song F, Loke YK, Walsh T, Glenny A-M, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ. 2009;338(7700):932–5.
  
• 作者单位：Mohammad O. Tallouzi (1)
  David J. Moore (1)
  Melanie Calvert (1)
  Philip I. Murray (2)
  Nicholas Bucknall (3)
  Alastair K. Denniston (4)
  
  1. Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
  2. Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
  3. Birdshot Uveitis Society representative, Birmingham, UK
  4. Department of Ophthalmology, Queen Elizabeth hospital, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, B15 2WB, UK
  
• 刊物主题：Medicine/Public Health, general; Biomedicine general; Statistics for Life Sciences, Medicine, Health Sciences;
• 出版者：BioMed Central
• ISSN：2046-4053

文摘

Background Macular oedema (MO) describes the accumulation of fluid in the central part of the retina, known as the ‘macula’ which provides central vision. MO is the leading cause of sight loss in patients with intraocular inflammation (uveitis). There is a lack of consensus over the treatment of uveitic macular oedema (UMO). The proposed systematic review will evaluate the evidence on the effectiveness of pharmacological agents used to treat UMO. All systemic, local, or topical pharmacological agents will be included.